Directorship Changes
Directorship Changes
In the last few years, it has become increasingly evident that medicinal cannabis is not only revolutionising the way we manage specific health issues, it’s also quietly transforming the economic
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines, announces that further to the 6 June 2025 announcement, it
Shares in Celadon Pharmaceuticals PLC (AIM: CEL), a UK-based pharmaceutical company specialising in cannabis-based medicines, surged over 25% in early trading following a financial update.
Shares in Celadon Pharmaceuticals PLC (AIM: CEL) plummeted 50% in early trading due to delays in accessing £1.3 million of funding.
On Monday, Germany legalized recreational cannabis use, marking it the largest EU nation to do so, amidst strong opposition from some politicians and medical groups.
The illegal cannabis market in Britain, estimated at £2.6 billion annually, poses a significant challenge for authorities amidst growing interest in its use for pain relief.
Today, Germany marked its entry as the ninth nation to authorize the recreational use of cannabis.
After Germany’s cabinet greenlit new legislation permitting the recreational use and cultivation of cannabis, predictions have emerged that the rest of Europe, including the UK, may follow suit.
Ananda Developments Plc (AQSE: ANA), a developer of cannabinoid medicines, has secured the necessary funding to initiate a trial to test the effectiveness of its cannabidiol oil, MRX1, in treating
Ananda’s ambition is to be a leading provider of high-quality cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.
Ananda Developments (AQSE: ANA) is an AQUIS-listed healthcare company involved in the development of cannabinoid-based medicines with two concurrently running, third-party funded, Phase II randomised control trials (RCTs).